A Phase III multicenter, double-blind, placebo-controlled, study evaluating the safety, and efficacy of STR001 treatment in adults with Sudden Sensorineural Hearing Loss Multicentrická, dvojitě zaslepená, placebem kontrolovaná studie fáze III ke zhodnocení bezpečnosti a účinnosti léčby přípravkem STR001 u dospělÝch s náhlou neurosenzorickou ztrátou sluchu (SSHL)

Trial Profile

A Phase III multicenter, double-blind, placebo-controlled, study evaluating the safety, and efficacy of STR001 treatment in adults with Sudden Sensorineural Hearing Loss Multicentrická, dvojitě zaslepená, placebem kontrolovaná studie fáze III ke zhodnocení bezpečnosti a účinnosti léčby přípravkem STR001 u dospělÝch s náhlou neurosenzorickou ztrátou sluchu (SSHL)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Pioglitazone (Primary) ; Pioglitazone (Primary)
  • Indications Hearing loss
  • Focus Registrational; Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Strekin
  • Most Recent Events

    • 17 Jul 2017 Status changed from planning to recruiting.
    • 05 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top